全基因组测序揭示重症患儿中遗传病频发
本研究在单个英国中心的前瞻性队列中,对195个NICU/PICU家庭进行三联全基因组测序分析(共567份样本),21%的患儿获得潜在遗传病的分子诊断。90%的病例中患儿表型描述不能预测所鉴定的基因,支持在NICU/PICU采用基因无关检测策略。诊断影响了超过65%病例的临床管理(新生儿中达83%),包括调整治疗和护理路径及/或为姑息治疗决策提供依据。2-3周的周转时间足以影响大多数临床决策。作者认为全基因组测序有潜力成为部分重症患儿的一线诊断工具。
要点
- 在195个NICU/PICU家庭中,三联全基因组测序使21%的患儿获得潜在遗传病的分子诊断。
- 90%的病例中,患儿表型描述不能预测所鉴定的基因,支持基因无关检测策略。
- 诊断影响了超过65%病例的临床管理,新生儿中达83%,包括调整治疗、护理路径或姑息治疗决策。
- 2-3周的检测周转时间足以影响大多数临床决策。
- 作者认为全基因组测序有潜力成为部分重症患儿的一线诊断工具。
适用人群与场景
- 在英国单个中心的新生儿重症监护病房(NICU)和儿科重症监护病房(PICU)招募的前瞻性队列家庭。
处置流程与药物剂量
- 对NICU/PICU家庭进行三联全基因组测序分析,并与英国国家医疗服务体系合作开发研究流程,在招募后2-3周内提供经过验证的相关致病发现。
研究设计与关键结果
- 研究类型为前瞻性队列,共195个家庭接受全基因组分析(567份样本),21%的患儿获得潜在遗传病的分子诊断。
- 90%的病例中患儿表型描述不能预测所鉴定的基因。
- 诊断影响了超过65%病例的临床管理(新生儿中83%),包括调整治疗和护理路径及/或为姑息治疗决策提供依据。
- 2-3周的周转时间足以影响大多数临床决策。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为全基因组测序在重症患儿中是可接受的,三联分析有助于诊断。
- 作者认为基因无关方法能有效识别潜在遗传病,表型和症状主要用于数据解读而非基因选择。
- 作者认为全基因组测序分析有潜力成为部分重症患儿的一线诊断工具。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: With growing evidence that rare single gene disorders present in the neonatal period, there is a need for rapid, systematic, and comprehensive genomic diagnoses in ICUs to assist acute and long-term clinical decisions. This study aimed to identify genetic conditions in neonatal (NICU) and paediatric (PICU) intensive care populations.
METHODS: We performed trio whole genome sequence (WGS) analysis on a prospective cohort of families recruited in NICU and PICU at a single site in the UK. We developed a research pipeline in collaboration with the National Health Service to deliver validated pertinent pathogenic findings within 2-3 weeks of recruitment.
RESULTS: A total of 195 families had whole genome analysis performed (567 samples) and 21% received a molecular diagnosis for the underlying genetic condition in the child. The phenotypic description of the child was a poor predictor of the gene identified in 90% of cases, arguing for gene agnostic testing in NICU/PICU. The diagnosis affected clinical management in more than 65% of cases (83% in neonates) including modification of treatments and care pathways and/or informing palliative care decisions. A 2-3 week turnaround was sufficient to impact most clinical decision-making.
CONCLUSIONS: The use of WGS in intensively ill children is acceptable and trio analysis facilitates diagnoses. A gene agnostic approach was effective in identifying an underlying genetic condition, with phenotypes and symptomatology being primarily used for data interpretation rather than gene selection. WGS analysis has the potential to be a first-line diagnostic tool for a subset of intensively ill children.
参考来源
- French CE, Delon I, Dolling H, et al. Whole genome sequencing reveals that genetic conditions are frequent in intensively ill children. Intensive Care Med. 2019. PMID: 30847515. doi:10.1007/s00134-019-05552-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。